CFT1946   Click here for help

GtoPdb Ligand ID: 12623

Synonyms: CFT-1946
Compound class: Synthetic organic
Comment: CFT1946 is an orally bioavailable, mutant-seelctive BRAFV600X PROTAC type degrader, that was developed for anti-tumour potential. It uses a cereblon (CRBN)-binding moiety to engage the E3 ubiquitin ligase system. The chemical structure was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 20
Hydrogen bond donors 3
Rotatable bonds 12
Topological polar surface area 241.5
Molecular weight 958
XLogP 0.77
No. Lipinski's rules broken 3
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCN(C)S(=O)(=O)NC1=CC=C(C(=C1C#N)OC2=CC3=C(C=C2)N=CN([C@@H]4CC5(CCN(CC5)C(=O)CC6(CCN(CC6)C7=CC8=C(C=C7F)C(=NN8C)N9CCC(=O)NC9=O)O)OC4)C3=O)F
Isomeric SMILES CCN(C)S(=O)(=O)NC1=CC=C(F)C(OC2=CC3=C(C=C2)N=CN([C@H]4COC5(C4)CCN(CC5)C(=O)CC6(O)CCN(CC6)C7=CC8=C(C=C7F)C(=NN8C)N9CCC(=O)NC9=O)C3=O)=C1C#N
InChI InChI=1S/C45H49F2N11O9S/c1-4-53(2)68(64,65)52-35-8-6-32(46)40(31(35)24-48)67-28-5-7-34-29(19-28)42(61)58(26-49-34)27-22-45(66-25-27)12-17-56(18-13-45)39(60)23-44(63)10-15-55(16-11-44)37-21-36-30(20-33(37)47)41(51-54(36)3)57-14-9-38(59)50-43(57)62/h5-8,19-21,26-27,52,63H,4,9-18,22-23,25H2,1-3H3,(H,50,59,62)/t27-/m1/s1
InChI Key OCDRMYDQTIPVOI-HHHXNRCGSA-N
No information available.
Summary of Clinical Use Click here for help
CFT1946 has been progressed to clinical evaluation, in a trial that was initiated in December 2022. NCT05668585 is recruiting patients with advanced, solid tumours that harbour BRAFV600 mutations.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05668585 A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors Phase 1/Phase 2 Interventional C4 Therapeutics, Inc.